Statement on therapies for high-risk, nonhospitalized patients with mild to moderate Covid-19.
The COVID-19 Treatment Guidelines Panel’s Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19 – NIH COVID-19 Treatment Guidelines See also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines
The post Statement on therapies for high-risk, nonhospitalized patients with mild to moderate Covid-19. appeared first on Links Medicus.
Omicron’s feeble attack on the lungs could make it less dangerous.
Omicron’s feeble attack on the lungs could make it less dangerous – Nature
The post Omicron’s feeble attack on the lungs could make it less dangerous. appeared first on Links Medicus.
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19.
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid Advisory for Ontario Commentary on Twitter Fantastic outpatient treatment approach from Ontario #COVID19 Clinical Practice GuidelinesRisk level:high mod lowEg:high:Sotrovimab is recommended if NA Remdesivir if NA Fluvoxamine or BudesonidePaxlovid/Molnupiravir not added coz not yet approved CA https://t.co/dDhj6vA0uv pic.twitter.com/4ucrKIcMn8 — […]
The post Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19. appeared first on Links Medicus.
M-A: Fatigue and cognitive impairment in Post-COVID-19 Syndrome.
Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis – Brain, Behavior, and Immunity
The post M-A: Fatigue and cognitive impairment in Post-COVID-19 Syndrome. appeared first on Links Medicus.
Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.
Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery – New England Journal of Medicine Commentary on Twitter In @NEJM today, @TerezaKasaeva @doctorsoumya and I write about Covid-19’s devastating impact on tuberculosis care & offer suggestions for recoveryhttps://t.co/buOEOPVWwM pic.twitter.com/BfOK3X3MuU — Madhu Pai, MD, PhD (@paimadhu) January 5, 2022
The post Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery. appeared first on Links Medicus.
Review: Rapid diagnostic testing for SARS-CoV-2.
Rapid Diagnostic Testing for SARS-CoV-2 – New England Journal of Medicine
The post Review: Rapid diagnostic testing for SARS-CoV-2. appeared first on Links Medicus.
Cohort study: Among health care workers previously vaccinated with 2 doses of the Pfizer-BioNTech vaccine, receiving a third dose was associated with reduced risk of SARS-CoV-2 infection.
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel – JAMA Editorial: Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection – JAMA
The post Cohort study: Among health care workers previously vaccinated with 2 doses of the Pfizer-BioNTech vaccine, receiving a third dose was associated with reduced risk of SARS-CoV-2 infection. appeared first on Links Medicus.
Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.
Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine Commentaries: Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology
The post Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban. appeared first on Links Medicus.
[Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv News release: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine Commentary: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science
The post [Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations. appeared first on Links Medicus.
Diagnostics for COVID-19: moving from pandemic response to control.
Diagnostics for COVID-19: moving from pandemic response to control – The Lancet Commentary on Twitter Diagnostics—crucial during the #COVID19 pandemic. A new Review discusses the 3 major methods for detection of SARS-CoV-2 infection & their evolution over time: moving from pandemic response to control. Learn more ? https://t.co/6Him1H3VG7 pic.twitter.com/jt7yHkolCK — The Lancet (@TheLancet) December […]
The post Diagnostics for COVID-19: moving from pandemic response to control. appeared first on Links Medicus.